PBH vs. RARE, HCM, AXSM, BHVN, XENE, SMMT, IDYA, CRNX, JANX, and ARWR
Should you be buying Prestige Consumer Healthcare stock or one of its competitors? The main competitors of Prestige Consumer Healthcare include Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Axsome Therapeutics (AXSM), Biohaven (BHVN), Xenon Pharmaceuticals (XENE), Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA), Crinetics Pharmaceuticals (CRNX), Janux Therapeutics (JANX), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical preparations" industry.
Prestige Consumer Healthcare (NYSE:PBH) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation.
Prestige Consumer Healthcare has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
In the previous week, Prestige Consumer Healthcare had 26 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 29 mentions for Prestige Consumer Healthcare and 3 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.62 beat Prestige Consumer Healthcare's score of 0.33 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.
Prestige Consumer Healthcare currently has a consensus target price of $95.00, indicating a potential upside of 46.95%. Ultragenyx Pharmaceutical has a consensus target price of $87.85, indicating a potential upside of 109.81%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Prestige Consumer Healthcare.
Ultragenyx Pharmaceutical received 322 more outperform votes than Prestige Consumer Healthcare when rated by MarketBeat users. Likewise, 77.11% of users gave Ultragenyx Pharmaceutical an outperform vote while only 70.61% of users gave Prestige Consumer Healthcare an outperform vote.
Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.
Prestige Consumer Healthcare has a net margin of 18.60% compared to Ultragenyx Pharmaceutical's net margin of -138.58%. Prestige Consumer Healthcare's return on equity of 13.48% beat Ultragenyx Pharmaceutical's return on equity.
100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 6.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Prestige Consumer Healthcare and Ultragenyx Pharmaceutical tied by winning 9 of the 18 factors compared between the two stocks.
Get Prestige Consumer Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prestige Consumer Healthcare Competitors List
Related Companies and Tools
